Genome of the Bacterium Streptococcus pneumoniae Strain R6
JoAnn Hoskins,William E. Alborn,Jeffrey Arnold,Larry C. Blaszczak,Stanley Burgett,Bradley S. DeHoff,Shawn T. Estrem,Lori Fritz,Dong-Jing Fu,Wendy Fuller,Chad Geringer,Raymond Gilmour,Jennifer S. Glass,Hamid Khoja,Angelika R. Kraft,Robert E. Lagace,Donald J. LeBlanc,Linda N. Lee,Elliot J. Lefkowitz,Jin Lu,Patti Matsushima,Scott M. McAhren,Margaret McHenney,Kevin McLeaster,Christopher W. Mundy,Thalia I. Nicas,Franklin H. Norris,MaryJeanne O'Gara,Robert B. Peery,Gregory T. Robertson,Pamela Rockey,Pei-Ming Sun,Malcolm E. Winkler,Yong Yang,Michelle Young-Bellido,Genshi Zhao,Christopher A. Zook,Richard H. Baltz,S. Richard Jaskunas,Paul R. Rosteck,Paul L. Skatrud,John I. Glass
DOI: https://doi.org/10.1128/jb.183.19.5709-5717.2001
IF: 3.2
2001-10-01
Journal of Bacteriology
Abstract:ABSTRACT Streptococcus pneumoniae is among the most significant causes of bacterial disease in humans. Here we report the 2,038,615-bp genomic sequence of the gram-positive bacterium S. pneumoniae R6. Because the R6 strain is avirulent and, more importantly, because it is readily transformed with DNA from homologous species and many heterologous species, it is the principal platform for investigation of the biology of this important pathogen. It is also used as a primary vehicle for genomics-based development of antibiotics for gram-positive bacteria. In our analysis of the genome, we identified a large number of new uncharacterized genes predicted to encode proteins that either reside on the surface of the cell or are secreted. Among those proteins there may be new targets for vaccine and antibiotic development.
microbiology